SB
ZYME icon

Samsara BioCapital’s Zymeworks ZYME Stock Holding History

Samsara BioCapital’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-207,901
Closed -$3.55M – 29
2025
Q3 		$3.55M Sell
207,901
-102,399
-33% -$1.47M 0.46% 20
2025
Q2 		$3.89M Sell
310,300
-356,367
-53% -$4.25M 0.8% 17
2025
Q1 		$7.94M Sell
666,667
-333,333
-33% -$4.55M 1.42% 12
2024
Q4 		$14.6M Hold
1,000,000
– – 2.01% 10
2024
Q3 		$12.6M Hold
1,000,000
– – 2.41% 11
2024
Q2 		$8.51M Sell
1,000,000
-458,875
-31% -$4.08M 1.78% 16
2024
Q1 		$15.3M Hold
1,458,875
– – 2.37% 12
2023
Q4 		$15.2M Hold
1,458,875
– – 2.36% 10
2023
Q3 		$9.25M Hold
1,458,875
– – 2.83% 11
2023
Q2 		$12.6M Sell
1,458,875
-161,812
-10% -$1.45M 2.21% 8
2023
Q1 		$14.7M Hold
1,620,687
– – 3.03% 8
2022
Q4 		$12.7M Buy
1,620,687
+649,700
+67% +$4.57M 2.74% 10
2022
Q3 		$5.97M Hold
970,987
– – 1.39% 18
2022
Q2 		$5.15M Hold
970,987
– – 1.37% 18
2022
Q1 		$6.36M Buy
+970,987
New +$8.65M 1.6% 13

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Samsara BioCapital's ZYME Position: Q4 2025 in Review

Samsara BioCapital sold out of Zymeworks (ZYME) in Q4 2025, closing a stake of 207,901 shares — an estimated $3.55M sold.

Samsara BioCapital first reported a position in ZYME in Q1 2022 and held it in 15 quarters. The position peaked at $15.3M in Q1 2024. 209 funds tracked by Wall St. Rank hold ZYME as of Q4 2025.

  • Samsara BioCapital reported no remaining Zymeworks position as of Q4 2025 after selling out during the quarter.
  • Samsara BioCapital sold 207,901 Zymeworks shares in Q4 2025, an estimated $3.55M.
  • Samsara BioCapital first reported a position in Zymeworks in Q1 2022 and held it in 15 quarters.
  • Samsara BioCapital's Zymeworks position peaked at $15.3M in Q1 2024.
  • 209 funds tracked by Wall St. Rank held Zymeworks as of Q4 2025.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.